BibTex RIS Cite

Poliklinikte Hiperlipidemik Hasta Takibi

Year 2010, Volume: 2010 Issue: 1, 39 - 41, 01.01.2010

Abstract

Koroner kalp hastalığı, Türkiye'de başta gelen morbidite ve mortalite nedenidir ve Türk halkında koroner hastalık için en önemli öngördürücü risk faktörlerinden biri total/yüksek yoğunluklu lipoprotein (HDL) kolesterol oranıdır. Dolaysıyla, dislipideminin, özellikle statinlerle uygun tedavisi, koroner kalp hastalığının önlenmesi açısından çok önemlidir. Ancak Türkiye'de lipid düşürücü tedavi suboptimal şekilde uygulanmaktadr. Bu açıdan hem hastalar, hem de hekimler tarafından yapılması gereken çok şey vardır.

References

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
  • Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007;194:1-45.

Follow-up of Patients with Hyperlipidemia in Policlinic

Year 2010, Volume: 2010 Issue: 1, 39 - 41, 01.01.2010

Abstract

Coronary heart disease is the leading cause of morbidity and mortality in Turkey and one of the most predictive risk factors of coronary disease in Turkish population is the ratio of total/HDL cholesterol. Therefore, adequate treatment of dyslipidemia, particularly with statins is very important with regard to prevention of coronary heart disease. However, lipid-lowering therapy is implemented suboptimally in Turkey. There is much to do for both patients and physicians. Koroner kalp hastalığı, Türkiye'de başta gelen morbidite ve mortalite nedenidir ve Türk halkında koroner hastalık için en önemli öngördürücü risk faktörlerinden biri total/yüksek yoğunluklu lipoprotein (HDL) kolesterol oranıdır. Dolaysıyla, dislipideminin, özellikle statinlerle uygun tedavisi, koroner kalp hastalığının önlenmesi açısından çok önemlidir. Ancak Türkiye'de lipid düşürücü tedavi suboptimal şekilde uygulanmaktadr. Bu açıdan hem hastalar, hem de hekimler tarafından yapılması gereken çok şey vardır.

References

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
  • Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007;194:1-45.
There are 3 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Ersan Tatlı This is me

Publication Date January 1, 2010
Published in Issue Year 2010 Volume: 2010 Issue: 1

Cite

APA Tatlı, E. (2010). Poliklinikte Hiperlipidemik Hasta Takibi. Balkan Medical Journal, 2010(1), 39-41.
AMA Tatlı E. Poliklinikte Hiperlipidemik Hasta Takibi. Balkan Medical Journal. January 2010;2010(1):39-41.
Chicago Tatlı, Ersan. “Poliklinikte Hiperlipidemik Hasta Takibi”. Balkan Medical Journal 2010, no. 1 (January 2010): 39-41.
EndNote Tatlı E (January 1, 2010) Poliklinikte Hiperlipidemik Hasta Takibi. Balkan Medical Journal 2010 1 39–41.
IEEE E. Tatlı, “Poliklinikte Hiperlipidemik Hasta Takibi”, Balkan Medical Journal, vol. 2010, no. 1, pp. 39–41, 2010.
ISNAD Tatlı, Ersan. “Poliklinikte Hiperlipidemik Hasta Takibi”. Balkan Medical Journal 2010/1 (January 2010), 39-41.
JAMA Tatlı E. Poliklinikte Hiperlipidemik Hasta Takibi. Balkan Medical Journal. 2010;2010:39–41.
MLA Tatlı, Ersan. “Poliklinikte Hiperlipidemik Hasta Takibi”. Balkan Medical Journal, vol. 2010, no. 1, 2010, pp. 39-41.
Vancouver Tatlı E. Poliklinikte Hiperlipidemik Hasta Takibi. Balkan Medical Journal. 2010;2010(1):39-41.